Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Drospirenone/ethinylestradiol low-dose - Bayer HealthCare Pharmaceuticals

Drug Profile

Drospirenone/ethinylestradiol low-dose - Bayer HealthCare Pharmaceuticals

Alternative Names: BAY86-5300; BAY86-5300-YAZ-Flex; Dihydrospirorenone/ethinylestradiol low-dose; EE20/Drospirenone; EE20/DRSP; Ethinylestradiol-Drospirenone 24+4; Flexyess; SH-T-00186D; Yasmin® 20; Yasminelle; Yaz; Yaz 24+4; Yaz Extended Cycle; YAZ Extended Regimen; Yaz Flex; Yvidually

Latest Information Update: 17 Jan 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Bayer HealthCare Pharmaceuticals; Bayer Schering Pharma
  • Developer Bayer HealthCare Pharmaceuticals; Bayer HealthCare Pharmaceuticals Inc.
  • Class Alkylated estrogenic steroids; Androstenes; Norpregnatrienes; Oral contraceptives; Progesterone congeners; Small molecules
  • Mechanism of Action Estrogen receptor agonists; Progesterone receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Acne; Dysmenorrhoea; Pregnancy; Premenstrual dysphoric disorder; Premenstrual syndrome
  • No development reported Endometriosis

Most Recent Events

  • 24 Jun 2018 Biomarkers information updated
  • 17 Jan 2018 No development reported - Phase-III for Acne in China (PO)
  • 17 Jan 2018 No development reported - Phase-III for Endometriosis in Japan (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top